Medidata encourages collaboration; files IPO

By Nick Taylor

- Last updated on GMT

Related tags: Medidata rave, Clinical trial, Medidata

Medidata has launched a programme to encourage interoperability and data sharing across clinical trial technologies, which should help cope with the complexity of modern research.

The Technology Partner Program forms part of Medidata’s efforts to increase collaboration between clinical technology providers.

This has seen the company launch Medidata Developer Central and Medidata Rave Web Service API, which help companies integrate software into Medidata Rave.

Explaining the approach Glen de Vries, president of Medidata, said: “A narrow, single-vendor approach presents obstacles in today’s complex clinical research environment. Sponsors and CROs continue to rely on their choice of technologies like Medidata Rave that work with other systems and help them to achieve their clinical development goals​.”

The programme is an acknowledgement that clients may use software from an array of providers in their clinical trials and an attempt to improve integration of these tools.

Medidata hopes that its programme will usher in a period of increased collaboration, with other eClinical providers joining the initial six that are integrating their technologies into Medidata Rave.

Our new Technology Partner Program is designed to lay the foundation for industry-wide collaboration and innovation, and Medidata remains committed to partnering with other industry leaders to allow customers to flexibly build an optimal eClinical environment​”, explained de Vries.

Currently Almac Clinical Technologies, CRF Health, invivodata, PHT, SAS and United BioSource Corporation have signed up to integrate technologies into Medidata Rave.

Medidata IPO this week

Medidata’s initial public offering (IPO) is due to take place this week, with the company hoping to raise up to $80m by listing itself on the NASDAQ stock exchange.

The company is the first that has never posted an annual profit to file an IPO this year, which could put off investors in what could be the busiest week for IPO since May 2008.

In its favour Medidata can point to its Q1 profit, rising revenues and the large number of major pharmas that use its software.

Related topics: Clinical Development

Related news

Show more

Follow us

Products

View more

Webinars